PLoS ONE (Jan 2016)

Switch to Dolutegravir plus Rilpivirine Dual Therapy in cART-Experienced Subjects: An Observational Cohort.

  • Amedeo F Capetti,
  • Gaetana Sterrantino,
  • Maria Vittoria Cossu,
  • GianCarlo Orofino,
  • Giorgio Barbarini,
  • Giuseppe V De Socio,
  • Simona Di Giambenedetto,
  • Antonio Di Biagio,
  • Benedetto M Celesia,
  • Barbara Argenteri,
  • Giuliano Rizzardini

DOI
https://doi.org/10.1371/journal.pone.0164753
Journal volume & issue
Vol. 11, no. 10
p. e0164753

Abstract

Read online

IntroductionLittle information is available on the efficacy and safety of the dual combination of ripivirine plus dolutegravir. This work aims at beginning to fill this gap.MethodsAll HIV-1 infected subjects treated with ripivirine plus dolutegravir between October 2014 and September 2015 in eight Italian centres were included in an observational cohort. Data were collected at baseline and at weeks 4, 12, 24 and 48.ResultsOne hundred and thirty-two subjects were followed for a median of 24 months, mean 33 months. One subject discontinued the study drug at week 24 for headache, one for drug interaction and one died after week 24 of illicit drug abuse. The mean age was 51.8, females 31.7% and non-caucasians 10%. Fifty-seven (43.2%) had at least one failure in their treatment history. Reasons for switching were simplification (53.0%), toxicity (34.8%), drug interactions (n = 7), persistent low-level viremia (n = 4), non-adherence (n = 3) and viral failure (n = 2). Sixty patients (45.5%) had reverse transcriptase (RT) mutations and 69 (44,7%) had protease (PR) mutations. Sixteen had baseline viral replication, 27 had ConclusionsRipivirine plus dolutegravir proved safe and effective in this cohort of non-naïve HIV-1 infected subjects.